Liang R, Todd D, Chan T K, Chiu E, Lie A, Kwong Y L, Choy D, Ho F C
University Department of Medicine, Queen Mary Hospital, Hong Kong.
Hematol Oncol. 1995 May-Jun;13(3):153-63. doi: 10.1002/hon.2900130305.
The gastrointestinal tract is a common primary extranodal site for non-Hodgkin's lymphoma. There is however no uniform consensus on its pathological classification, clinical staging system and management. This paper reports the experience in the management of 425 Chinese patients with primary gastrointestinal lymphoma in Hong Kong from January 1975 to June 1993. There were 230 (54 per cent) males and 195 (46 per cent) females. Their median age was 53 years. The primary sites were: the esophagus in three (1 per cent), stomach in 238 (56 per cent), small intestine in 131 (31 per cent) and large intestine in 53 (12 per cent). According to the Working Formulation, there were 20 (4.7 per cent) small lymphocytic, 10 (2.4 per cent) follicular small cleaved cell, 15 (3.5 per cent) follicular mixed, five (1.2 per cent) follicular large cell, 40 (9.4 per cent) diffuse small cleaved cell, 50 (12 per cent) diffuse mixed, 181 (43 per cent) diffuse large cell, 30 (7.1 per cent) immunoblastic, five (1.2 per cent) lymphoblastic, 10 (2.4 per cent) diffuse small non-cleaved cell and 50 (14 per cent) unclassifiable lymphoma. Immunophenotyping was performed in 199 (47 per cent) patients: 90 per cent B-cell, 7 per cent T-cell and 3 per cent uncertain. According to a Manchester system, 81 (19 per cent) patients had stage I disease, 44 (10 per cent) stage II, 85 (20 per cent) stage III and 215 (51 per cent) stage IV. B symptoms were present in 275 (65 per cent) patients and bulky disease in 104 (25 per cent). Surgery followed by chemotherapy was the mainstay of treatment. Of the 408 patients treated, 63 per cent had a complete remission with relapse rate of 42 per cent. For those with complete remission, 47 per cent were free from disease at 5 years. The overall median survival of all patients was 45 per cent at 5 years. Multivariate analysis revealed that significant independent prognostic factors predicting better survival were young age of < 60 years, low grade histology, stage I and II disease and absence of bulky tumour. For gastric lymphoma, aggressive surgery did not significantly improve their outcome. Chemotherapy appears to play an important role in the management of gastrointestinal lymphoma. Better classification of the primary gastrointestinal lymphoma and more refined stratification of the patients according to the prognostic variables may allow individualization of treatment. Prospective randomized studies are essential to define the relative roles of surgery, chemotherapy and radiotherapy.
胃肠道是非霍奇金淋巴瘤常见的结外原发部位。然而,对于其病理分类、临床分期系统及治疗方法尚无统一的共识。本文报告了1975年1月至1993年6月香港地区425例原发性胃肠道淋巴瘤中国患者的治疗经验。其中男性230例(54%),女性195例(46%)。他们的中位年龄为53岁。原发部位分别为:食管3例(1%),胃238例(56%),小肠131例(31%),大肠53例(12%)。根据工作分类法,小淋巴细胞型20例(4.7%),滤泡性小裂细胞型10例(2.4%),滤泡性混合型15例(3.5%),滤泡性大细胞型5例(1.2%),弥漫性小裂细胞型40例(9.4%),弥漫性混合型50例(12%),弥漫性大细胞型181例(43%),免疫母细胞型30例(7.1%),淋巴母细胞型5例(1.2%),弥漫性小无裂细胞型10例(2.4%),无法分类的淋巴瘤50例(14%)。199例(47%)患者进行了免疫表型分析:90%为B细胞型,7%为T细胞型,3%不确定。根据曼彻斯特分期系统,81例(19%)患者为Ⅰ期,44例(10%)为Ⅱ期,85例(20%)为Ⅲ期,215例(51%)为Ⅳ期。275例(65%)患者有B症状,104例(25%)有大包块病变。治疗以手术加化疗为主。在接受治疗的408例患者中,63%完全缓解,复发率为42%。完全缓解的患者中,47%在5年后无病生存。所有患者5年总体中位生存率为45%。多因素分析显示,预测生存较好的显著独立预后因素为年龄<60岁、低级别组织学类型、Ⅰ期和Ⅱ期疾病以及无大包块肿瘤。对于胃淋巴瘤,积极手术并未显著改善其预后。化疗在胃肠道淋巴瘤的治疗中似乎起着重要作用。对原发性胃肠道淋巴瘤进行更好的分类,并根据预后变量对患者进行更精细的分层,可能使治疗个体化。前瞻性随机研究对于明确手术、化疗和放疗的相对作用至关重要。